Akeso, Inc.
9926
Rang in aandelen
#1937
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery,... Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
Aandeelprijs
$11.83
Marktkapitalisatie
$10.89B
Verandering (1 dag)
1.15%
Verandering (1 jaar)
-23.08%
Land
CN
Handel Akeso, Inc. (9926)
Categorie
Healthcare
Aantal uitstaande aandelen voor Akeso, Inc. (9926)
Aantal uitstaande aandelen per June 2026: 918.64M
Volgens de laatste financiële rapporten en de aandelenkoers van Akeso, Inc. bedraagt het huidige aantal uitstaande aandelen 918.64M. Aan het einde van December 2023 had het bedrijf 837.82M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Akeso, Inc. (9926) van 2018 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 918.64M | 7.95% |
| 2024 | 851.03M | 1.58% |
| 2023 | 837.82M | 1.56% |
| 2022 | 824.99M | 1.11% |
| 2021 | 815.93M | 29.73% |
| 2020 | 628.94M | 510.80% |
| 2019 | 102.97M | -86.51% |
| 2018 | 763.13M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 253.90M | -72.36% |
US
|
|
| 396.00M | -56.89% |
US
|
|
| 478.91M | -47.87% |
AU
|
|
| 62.19M | -93.23% |
NL
|
|
| - | - |
CH
|
